Community Dynamics of Malaria Transmission and Mosquito Feeding in Bancoumana, Mali

Launched by NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID) · Oct 6, 2017

Keywords

ClinConnect Summary

A vaccine that interrupts malaria transmission is critical to eradicate the disease, but improved assays are needed to measure the efficacy of vaccines. Transmission-blocking vaccines (TBVs) work by inducing antibodies in vaccinees that inhibit parasite development in the mosquito interrupting transmission. Efficacy of vaccines may be estimated by in vitro membrane feeding assays using immune sera and laboratory mosquitoes, but qualified assays that measure transmission in the field are needed to assess transmission-blocking interventions in natura. Clinical trials of TBV have started in Ba...

Gender

ALL

Eligibility criteria

• * INCLUSION CRITERIA:
• • GENOTYPE ONLY COHORT
• • Any age
• • Known resident of Bancoumana or the surrounding villages
• • Acceptance and signature of the written informed consent and the assent for children aged 12-17 years
• • Willingness to allow stored laboratory specimens to be used for future research
• • PARASITE SURVEILLANCE COHORT
• • 6 months to 65 years of age
• • Known resident of Bancoumana or the surrounding villages
• • Willingness to allow stored laboratory specimens to be used for future research
• • Acceptance and signature of the written informed consent and the assent for children aged 12-17 years
• • DSF COHORT
• • Aged between 5 and 65 years, inclusive
• • Good general health as determined by review of medical history and/or clinical testing at the time of screening
• • Known resident of Bancoumana or the surrounding villages
• • Willingness to allow stored laboratory specimens to be used for future research
• • Willingness to undergo DSF
• • Acceptance and signature of the written informed consent and the assent for children aged 12-17 years
• EXCLUSION CRITERIA:
• • GENOTYPE ONLY COHORT
• • Behavioral, cognitive, or psychiatric disease that in the opinion of the investigator affects the ability of the subject to understand and cooperate with the study protocol
• • Other condition that, in the opinion of the investigator, would jeopardize the safety or rights of a volunteer participating in the trial or would render the subject unable to comply with the protocol
• • PARASITE SURVEILLANCE CHORT
• • Behavioral, cognitive, or psychiatric disease that in the opinion of the investigator affects the ability of the subject to understand and cooperate with the study protocol
• • Other condition that, in the opinion of the investigator, would jeopardize the safety or rights of a volunteer participating in the trial or would render the subject unable to comply with the protocol
• • Currently enrolled participant in protocol 17-I-N006 or another active LMIV/MRTC vaccine clinical trial
• • DSF COHORT
• • Behavioral, cognitive, or psychiatric disease that in the opinion of the investigator affects the ability of the subject to understand and cooperate with the study protocol
• • Other condition that, in the opinion of the investigator, would jeopardize the safety or rights of a volunteer participating in the trial or would render the subject unable to comply with the protocol
• • Currently enrolled participant in protocol 17-I-N006 or another LMIV/MRTC vaccine clinical trial
• • History of severe reaction to mosquito bites